Zobrazeno 1 - 7
of 7
pro vyhledávání: '"C Folguera Olias"'
Autor:
R De Santiago Álvarez, C Hernández Terciado, JI Alcaraz López, C Lozano Llano, L Delgado Téllez De Cepeda, B Menchén Viso, C Folguera Olias, M Manso Manrique, C Maximiano Alonso, A Sánchez Guerrero
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::050d660bab0baf9e18f52de4e5b3fa8b
https://doi.org/10.1136/ejhpharm-2023-eahp.403
https://doi.org/10.1136/ejhpharm-2023-eahp.403
Autor:
C Folguera Olias, A de Rivas Bravo, B. Menchén Viso, A Maestro Nombela, A Martín Alonso, A Sánchez Guerrero
Publikováno v:
European Journal of Hospital Pharmacy. 23:A72.1-A72
Background Multiple sclerosis (MS) involves an immune mediated process in which an abnormal response of the body’s immune system is directed against the central nervous system. For years, MS has been treated only with intravenous drugs. For this re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bb5091d0d0892455986357160f09957
https://doi.org/10.1136/ejhpharm-2016-000875.163
https://doi.org/10.1136/ejhpharm-2016-000875.163
Autor:
A Diez Alcantara, A Torralba Arranz, V Alonso Castro, C Folguera Olias, BM Escudero Vilaplana
Publikováno v:
European Journal of Hospital Pharmacy. 21:A71.2-A71
Background Pazopanib is a protein kinase inhibitor. It is indicated in adults for the treatment of advanced Renal Cell Carcinoma (RCC) and the treatment of patients with particular subtypes of advanced Soft Tissue Sarcoma (STS). Purpose To evaluate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ee1ee5b15073c8b7d804121fb7b0a7d
https://doi.org/10.1136/ejhpharm-2013-000436.175
https://doi.org/10.1136/ejhpharm-2013-000436.175
Autor:
V Saavedra-Quirós, A Díaz-Alcántara, B Escudero-Vilaplana, C Folguera-Olias, A Martín-Alonso, A Torralba-Arranz
Publikováno v:
European Journal of Hospital Pharmacy. 20:A98.1-A98
Background Recently the use of IV carboxymaltose iron at doses of 500–1000 mg has increased in our hospital, even though it is not included in the formulary and it should be only used to avoid blood transfusions. Purpose To evaluate the use of carb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39b9d894e250f955d4178c1d2a8c0dfd
https://doi.org/10.1136/ejhpharm-2013-000276.274
https://doi.org/10.1136/ejhpharm-2013-000276.274
Publikováno v:
European Journal of Hospital Pharmacy. 20:A113.1-A113
Background The expectations raised by the new oral anticoagulants (OACs) have led some experts to view them as the ideal substitute for anti-vitamin K. Purpose To analyse the use of dabigatran and rivaroxaban in a Spanish tertiary hospital since thei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2492c381360721b70d276afa4695770
https://doi.org/10.1136/ejhpharm-2013-000276.314
https://doi.org/10.1136/ejhpharm-2013-000276.314
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.